ArticleCancer chemotherapy and pharmacology2020

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.

Ken Ogasawara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.